{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:20:14Z","timestamp":1790716814593,"version":"4.1.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s66309","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T22:18:50Z","timestamp":1405549130000},"page":"357","source":"Crossref","is-referenced-by-count":31,"title":["Oncology drug health technology assessment recommendations: Canadian versus UK experiences"],"prefix":"10.2147","author":[{"given":"Isabelle","family":"Chabot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,7]]},"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=20862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:31:11Z","timestamp":1477852271000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/oncology-drug-health-technology-assessment-recommendations-canadian-ve-peer-reviewed-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ceor.s66309","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}